Results that please your patients.
“The improvement was like going from night to day.”
— 58-year-old man treated with Varithena
Thurman’s veins stuck out in his thigh and lower leg and would hurt at night, making it hard to sleep. Aching and pain prevented him from doing what he wanted to do. But he didn’t want to have his veins “stripped” so he delayed treatment and suffered with the pain and immobility—until he had them treated with Varithena.
Add to your practice with this versatile, efficient, and consistent varicose vein treatment. Order directly from Boston Scientific.
Become Varithena certified
Join the 2,000+ certified physicians improving patients’ lives with Varithena. We’re here to help you, and becoming certified is easy.
Contact a sales representative
Have your local Varithena
Join the physician
Patients want to know who’s performing Varithena procedures. Get noticed by potential patients.
- Patients reporting pain at injection or application site in clinical trials was 4.0%. BSC data on file.
- Todd KL III, Wright DI, and the VANISH-2 Investigator Group. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology. 2014;29(9):608-618. doi:10.1177/0268355513497709.
Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Important Safety Information
The use of Varithena® is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately. Varithena® can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis. Physicians administering Varithena® must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena®.
See Full Prescribing Information for Varithena®